Page 336 - Williams Hematology ( PDFDrive )

310 Part IV: Molecular and Cellular Hematology Chapter 21: Dendritic Cells and Adaptive Immunity 311

11. Pulendran B: Modulating vaccine responses with dendritic cells and Toll-like receptors. 47. Savina A, Peres A, Cebrian I, et al: The small GTPase Rac2 controls phagosomal alka-
Immunol Rev 199:227–250, 2004. linization and antigen crosspresentation selectively in CD8(+) dendritic cells. Immunity
12. Gilliet M, Cao W, Liu YJ: Plasmacytoid dendritic cells: Sensing nucleic acids in viral 30:544–555, 2009.
infection and autoimmune diseases. Nat Rev Immunol 8:594–606, 2008. 48. Segura E, Amigorena S: Cross-presentation by human dendritic cell subsets. Immunol
13. Zhu J, Paul WE: CD4 T cells: Fates, functions, and faults. Blood 112:1557–1569, 2008. Lett 158:73–78, 2014.
14. Dhodapkar MV, Steinman RM, Krasovsky J, et al: Antigen-specific inhibition of effec- 49. Bachem A, Guttler S, Hartung E, et al: Superior antigen cross-presentation and XCR1
tor T cell function in humans after injection of immature dendritic cells. J Exp Med expression define human CD11c+CD141+ cells as homologues of mouse CD8+ den-
193:233–238, 2001. dritic cells. J Exp Med 207:1273–1281, 2010.
15. Steinman RM, Hawiger D, Nussenzweig MC: Tolerogenic dendritic cells. Annu Rev 50. Granelli-Piperno A, Pritsker A, Pack M, et al: Dendritic cell-specific intercellular adhe-
Immunol 21:685–711, 2003. sion molecule 3-grabbing nonintegrin/CD209 is abundant on macrophages in the nor-
16. Yamazaki S, Dudziak D, Heidkamp GF, et al: CD8+ CD205+ splenic dendritic cells are mal human lymph node and is not required for dendritic cell stimulation of the mixed
specialized to induce Foxp3+ regulatory T cells. J Immunol 181:6923–6933, 2008. leukocyte reaction. J Immunol 175:4265–4273, 2005.
17. Granucci F, Vizzardelli C, Pavelka N, et al: Inducible IL-2 production by dendritic cells 51. Merad M, Sathe P, Helft J, et al: The dendritic cell lineage: Ontogeny and function of
revealed by global gene expression analysis. Nat Immunol 2:882–888, 2001. dendritic cells and their subsets in the steady state and the inflamed setting. Annu Rev
18. Huang Q, Liu D, Majewski P, et al: The plasticity of dendritic cell responses to pathogens Immunol 31:563–604, 2013.
and their components. Science 294:870–875, 2001. 52. Murphy KM: Transcriptional control of dendritic cell development. Adv Immunol
19. Geijtenbeek TB, Kwon DS, Torensma R, et al: DC-SIGN, a dendritic cell-specific HIV- 120:239–267, 2013.
1-binding protein that enhances trans-infection of T cells. Cell 100:587–597, 2000. 53. Meredith MM, Liu K, Darrasse-Jeze G, et al: Expression of the zinc finger transcrip-
20. Halary F, Amara A, Lortat-Jacob H, et al: Human cytomegalovirus binding to DC- tion factor zDC (Zbtb46, Btbd4) defines the classical dendritic cell lineage. J Exp Med
SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 209:1153–1165, 2012.
17:653–664, 2002. 54. Meredith MM, Liu K, Kamphorst AO, et al: Zinc finger transcription factor zDC is a
21. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, et al: DC-SIGN (CD209) mediates negative regulator required to prevent activation of classical dendritic cells in the steady
dengue virus infection of human dendritic cells. J Exp Med 197:823–829, 2003. state. J Exp Med 209:1583–1593, 2012.
22. van Kooyk Y, Geijtenbeek TB: DC-SIGN: Escape mechanism for pathogens. Nat Rev 55. Onai N, Obata-Onai A, Schmid MA, et al: Identification of clonogenic common
Immunol 3:697–709, 2003. Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse
23. Bonifaz LC, Bonnyay DP, Charalambous A, et al: In vivo targeting of antigens to matur- bone marrow. Nat Immunol 8:1207–1216, 2007.
ing dendritic cells via the DEC-205 receptor improves T cell vaccination. J Exp Med 56. Naik SH, Sathe P, Park HY, et al: Development of plasmacytoid and conventional den-
199:815–824, 2004. dritic cell subtypes from single precursor cells derived in vitro and in vivo. Nat Immunol
24. Liu K, Iyoda T, Saternus M, et al: Immune tolerance after delivery of dying cells to 8:1217–1226, 2007.
dendritic cells in situ. J Exp Med 196:1091–1097, 2002. 57. Liu K, Victora GD, Schwickert TA, et al: In vivo analysis of dendritic cell development
25. Inaba K, Turley S, Yamaide F, et al: Efficient presentation of phagocytosed cellular frag- and homeostasis. Science 324:392–397, 2009.
ments on the major histocompatibility complex class II products of dendritic cells. J 58. Steinman RM: Decisions about dendritic cells: Past, present, and future. Annu Rev
Exp Med 188:2163–2173, 1998. Immunol 30:1–22, 2012.
26. Hildner K, Edelson BT, Purtha WE, et al: Batf3 deficiency reveals a critical role for 59. Anandasabapathy N, Feder R, Mollah S, et al: Classical Flt3L-dependent dendritic cells
CD8alpha+ dendritic cells in cytotoxic T cell immunity. Science 322:1097–1100, 2008. control immunity to protein vaccine. J Exp Med 211:1875–1891, 2014.
27. Jung S, Unutmaz D, Wong P, et al: In vivo depletion of CD11c+ dendritic cells abrogates 60. Anguille S, Smits EL, Lion E, et al: Clinical use of dendritic cells for cancer therapy.
priming of CD8+ T cells by exogenous cell-associated antigens. Immunity 17:211–220, Lancet Oncol 15:e257-e267, 2014.
2002. 61. Palucka K, Banchereau J: Dendritic-cell-based therapeutic cancer vaccines. Immunity
28. Shimizu K, Kurosawa Y, Taniguchi M, et al: Cross-presentation of glycolipid from 39:38–48, 2013.
tumor cells loaded with alpha-galactosylceramide leads to potent and long-lived T cell 62. Hsu FJ, Benike C, Fagnoni F, et al: Vaccination of patients with B-cell lymphoma using
mediated immunity via dendritic cells. J Exp Med 204:2641–2653, 2007. autologous antigen-pulsed dendritic cells. Nat Med 2:52–58, 1996.
29. Wu DY, Segal NH, Sidobre S, et al: Cross-presentation of disialoganglioside GD3 to 63. Dhodapkar MV, Steinman RM, Krasovsky J, et al: Antigen specific inhibition of effec-
natural killer T cells. J Exp Med 198:173–181, 2003. tor T cell function in humans after injection of immature dendritic cells. J Exp Med
30. Kalergis AM, Ravetch JV: Inducing tumor immunity through the selective engagement 193:233–238, 2001.
of activating Fcgamma receptors on dendritic cells. J Exp Med 195:1653–1659, 2002. 64. Dhodapkar MV, Krasovsky J, Steinman RM, Bhardwaj N: Mature dendritic cells boost
31. Vincent MS, Gumperz JE, Brenner MB: Understanding the function of CD1-restricted functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin
T cells. Nat Immunol 4:517–523, 2003. Invest 105:R9–R14, 2000.
32. Fujii S, Liu K, Smith C, et al: The linkage of innate to adaptive immunity via maturing 65. Banerjee D, Dhodapkar MV, Matayeva E, et al: Expansion of FOXP3high regulatory
dendritic cells in vivo requires CD40 ligation in addition to antigen presentation and T cells by human dendritic cells (DCs) in vitro and after DC injection of cytokine
CD80/86 costimulation. J Exp Med 199:1607–1618, 2004. matured DCs in myeloma patients. Blood 108:2655–2661, 2006.
33. Schmid D, Pypaert M, Munz C: Antigen-loading compartments for major histocom- 66. Sznol M, Chen L: Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment
patibility complex class II molecules continuously receive input from autophagosomes. of advanced human cancer. Clin Cancer Res 19:1021–1034, 2013.
Immunity 26:79–92, 2007. 67. Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev
34. Schmid D, Munz C: Innate and adaptive immunity through autophagy. Immunity Cancer 12:252–264, 2012.
27:11–21, 2007. 68. Richter J, Neparidze N, Zhang L, et al: Clinical regressions and broad immune acti-
35. Paludan C, Schmid D, Landthaler M, et al: Endogenous MHC class II processing of a vation following combination therapy targeting human NKT cells in myeloma. Blood
viral nuclear antigen after autophagy. Science 307:593–596, 2005. 121:423–430, 2013.
36. Garrett WS, Chen LM, Kroschewski R, et al: Developmental control of endocytosis in 69. Hawiger D, Inaba K, Dorsett Y, et al: Dendritic cells induce peripheral T cell unrespon-
dendritic cells by Cdc42. Cell 102:325–334, 2000. siveness under steady state conditions in vivo. J Exp Med 194:769–779, 2001.
37. Trombetta ES, Ebersold M, Garrett W, et al: Activation of lysosomal function during 70. Dhodapkar MV, Sznol M, Zhao B, et al: Induction of antigen-specific immunity with
dendritic cell maturation. Science 299:1400–1403, 2003. a vaccine targeting NY-ESO-1 to the dendritic cell receptor DEC-205. Sci Transl Med
38. Inaba K, Turley S, Iyoda T, et al: The formation of immunogenic major histocompati- 6:232ra51, 2014.
bility complex class II-peptide ligands in lysosomal compartments of dendritic cells is 71. Kreutz M, Tacken PJ, Figdor CG: Targeting dendritic cells—Why bother? Blood
regulated by inflammatory stimuli. J Exp Med 191:927–936, 2000. 121:2836–2844, 2013.
39. Chow A, Toomre D, Garrett W, Mellman I: Dendritic cell maturation triggers ret- 72. Pulendran B, Tang H, Denning TL: Division of labor, plasticity, and crosstalk between
rograde MHC class II transport from lysosomes to the plasma membrane. Nature dendritic cell subsets. Curr Opin Immunol 20:61–67, 2008.
418:988–994, 2002. 73. Sehgal K, Ragheb R, Fahmy TM, et al: Nanoparticle-mediated combinatorial targeting
40. Shin JS, Ebersold M, Pypaert M, et al: Surface expression of MHC class II in dendritic of multiple human dendritic cell (DC) subsets leads to enhanced T cell activation via
cells is controlled by regulated ubiquitination. Nature 444:115–118, 2006. IL-15-dependent DC crosstalk. J Immunol 193:2297–2305, 2014.
41. Tezuka H, Abe Y, Iwata M, et al: Regulation of IgA production by naturally occurring 74. Hashimoto D, Merad M: Harnessing dendritic cells to improve allogeneic hematopoi-
TNF/iNOS-producing dendritic cells. Nature 448:929–933, 2007. etic cell transplantation outcome. Semin Immunol 23:50–57, 2011.
42. Fayette J, Dubois B, Vandenabeele S, et al: Human dendritic cells skew isotype switching 75. Merad M, Hoffmann P, Ranheim E, et al: Depletion of host Langerhans cells before
of CD40-activated naive B cells towards IgA1 and IgA2. J Exp Med 185:1909–1918, 1997. transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat
43. Macpherson AJ, Uhr T: Induction of protective IgA by intestinal dendritic cells carrying Med 10:510–517, 2004.
commensal bacteria. Science 303:1662–1665, 2004. 76. Toubai T, Mathewson N, Reddy P: The role of dendritic cells in graft-versus-tumor
44. Jego G, Palucka AK, Blanck JP, et al: Plasmacytoid dendritic cells induce plasma cell effect. Front Immunol 5:66, 2014.
differentiation through type I interferon and interleukin 6. Immunity 19:225–234, 2003. 77. Sehgal K, Guo X, Koduru S, et al: Plasmacytoid dendritic cells, interferon signaling,
45. Shortman K, Heath WR: The CD8+ dendritic cell subset. Immunol Rev 234:18–31, and FcγR contribute to pathogenesis and therapeutic response in childhood immune
2010. thrombocytopenia. Sci Transl Med 5:193ra89, 2013.
46. Dudziak D, Kamphorst AO, Heidkamp GF, et al: Differential antigen processing by den-
dritic cell subsets in vivo. Science 315:107–111, 2007.

Kaushansky_chapter 21_p0307-0312.indd 311 9/17/15 5:52 PM